dromlakhani Recommend against using GH to enhance athletic performance
STEP 1 — Gather Information
Collect the patient's reason for seeking GH (performance enhancement vs medical), assess for symptoms of GH deficiency, review pituitary history, and check baseline IGF-1 if available. Document the request and any evidence of GH deficiency.
STEP 2 — Rule In / Rule Out
If the patient has proven GH deficiency (failed stimulation test) and requests GH for therapeutic purposes, proceed to therapeutic planning. If the request is solely for athletic performance enhancement (no proven deficiency), rule out GH for this purpose. Ends with: Decision point — therapeutic request vs performance-only request.
STEP 3 — Classify or Stratify
For therapeutic requests, classify by age (<60 years: 0.2–0.4 mg/d starting dose; ≥60 years: 0.1–0.2 mg/d). For performance-only requests, classify as non‑indicated use. Ends with: Classification result.
STEP 4 — Decide
For therapeutic requests, initiate GH at age‑appropriate dose and titrate to keep IGF‑1 below the upper limit of normal. For performance‑only requests, recommend against GH use, counsel on illegality, lack of efficacy, and discuss risks (e.g., edema, insulin resistance). Ends with: Action — either start GH therapy or decline and educate.
Clinical Guardrails / Mimics / Pitfalls
Do not prescribe GH solely for athletic performance; do not overlook legal prohibitions; do not yield to patient pressure without discussing risks; do not confuse performance enhancement with legitimate GH deficiency treatment; monitor for side effects if GH is ever considered.
Concrete Clinical Example
A 25‑year‑old collegiate weightlifter requests GH to increase lean mass; IGF‑1 is normal and there is no pituitary pathology. You explain that GH is illegal for performance enhancement, lacks proven benefit, and carries risks such as edema and insulin resistance; you decline the request and advise on evidence‑based training and nutrition.
Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118